IXOTATUG VEDOTIN
UNII V2JQK5RVM3
Substance Identification & Data
This profile provides standardized clinical and technical data for Ixotatug Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) V2JQK5RVM3.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3018937-00-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
V2JQK5RVM3
3018937-00-0
N/A
Detailed Substance Profile
Preferred Name
IXOTATUG VEDOTIN
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13517
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
OP-79
Identifier assigned by the United States Adopted Names Council.
Substance Type
Ixotatug Vedotin
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Ixotatug Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Ixotatug Vedotin
Common Names & Synonyms
H-gamma1 heavy chain (1-447) [VH Musmus/Homsap (Mus musculus IGHV6-3*01 (88.8%) -(IGHD) -IGHJ2*01 (90.9%) T123>L (112)/Homo sapiens IGHV3-23*03 (82.7%) -(IGHD) -IGHJ5*01 (91.7%) V124>L (113), CDR-IMGT [8.10.8] (26-33.51-60.99-106)) (1-117) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV12-44*01 (83.2%) -IGKJ1*01 (91.7%) G120>Q (100')/Homo sapiens IGKV1-39*01 (83.2%) -IGKJ2*02 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-S, glycoform alfa; substituted at the sulfur atoms of an average of four L-cysteinyl residues among 220, 226, 229, 214', 220'', 226'', 229'' and 214''' with (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-32-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin) groups
IXOTATUG VEDOTIN [USAN]
Immunoglobulin G1, anti-(human claudin 6) (human monoclonal TORL-1-23 γ1-chain), disulfide with human monoclonal TORL-1-23 κ-chain, dimer, reduced, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
immunoglobulin G1-kappa, anti-[Homo sapiens CLDN6 (claudin 6, claudin-6)], monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE) (ixotatug vedotin)
ixotatug vedotin [INN]
Technical Codes
TORL-1-23 ADC
